Cardiff Oncology reported that median PFS has not been reached in the 30 mg onvansertib + FOLFIRI/bev arm versus approximately 11 months in combined standard-of-care arms. It is preparing a registrational Phase 3 trial with a potential Q1 2027 start.
CRDF · Cardiff Oncology, Inc. · Documents
Substantial doubt about the company's ability to continue as a going concern.
“Management has performed an analysis and concluded that there exists a substantial doubt about our ability to continue as a going concern, see Note 1 Business Organization and Overview - Going Concern Uncertainty to the financial statements for additional details.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Cardiff Oncology said onvansertib plus FOLFIRI/bev achieved a 72.2% confirmed objective response rate versus 42.1% for FOLFIRI/bev alone in first-line RAS-mutated mCRC, a 30 percentage point improvement. It plans a global Phase 3 trial enrolling approximately 640 patients.
Cardiff Oncology appointed Leila Alland, MD, interim Chief Medical Officer on October 23, 2026, succeeding Roger Sidhu, MD, who separated October 22, 2026. The company also increased authorized common stock to 300,000,000 shares.
Cardiff Oncology stockholders approved increasing authorized capital stock from 170,000,000 to 320,000,000 and authorized common stock from 150,000,000 to 300,000,000 at the October 22, 2026 Special Meeting.